AMD is the leading cause of vision loss in Europe, the United States and Australia 1 . Almost two-thirds of the population over 80 years of age will have signs of AMD 2-4 resulting from the wet or exudative form, which is characterized by the presence of drusen and CNV. The aim of the first studies performed on CNV associated with AMD was to compare mRNA and protein levels in human neovascular membranes excised surgically with intact choroids. Experimental animal models rapidly became essential for elucidating the cellular and molecular mechanisms involved in CNV pathogenesis and for screening new drugs. Indeed, no in vitro model developed to date recapitulates the complex CNV-associated processes that involve, at a minimum, several cell types, such as inflammatory cells, endothelial cells, pericytes, bone marrow (BM)-derived cells, myofibroblasts and glial cells 5, 6 . The in vivo exploration of CNV currently involves several mouse models exhibiting the spontaneous development of CNV resulting from a defective complement-activating pathway, deletion in a chemokine or chemokine receptor, oxidative damage or aging 7 . Currently, the laser-induced Bruch's membrane photocoagulation model is the most widely accepted and most frequently used experimental mouse CNV model. The model described here consists of the laser impact rupturing of Bruch's membrane, which leads to the growth of new blood vessels from the choroid into the subretinal space, mimicking the main characteristics of the exudative form of human AMD 8 and offering the opportunity to explore the molecular mechanism of CNV through the use of a large panel of transgenic mice. The model has proven to be suitable for testing the efficacy of new drugs through systemic or local (intraocular) administration and has shown predictive value for drug effects in patients with AMD, for example, with vascular endothelial growth factor receptor (VEGFR) trap 9,10 or anecortave acetate 11, 12 . This model is also appropriate for identifying new potential targets using the siRNA or miRNA technology 13 .
extractions. In contrast to the transgenic models that overexpress apolipoprotein E 31 or that have a deletion of superoxide dismutase 1 (ref. 32) , which are long-term assays requiring senescent animals, the laser-induced CNV assay can be applied to a panel of young wild-type or transgenic mice. The model is applicable to transgenic (knockout or knockin) mice. In addition, viruses, cells or compounds, including neutralizing antibodies, siRNA or shRNA, pre-miRNA, recombinant proteins, nanoparticles and drugs, can be administered via different pathways (i.p. injection, i.v. injection, per os, drinking water, intravitreous injection, subretinal injection, BM engraftment and others) and combined or not with genetic manipulation 9, [33] [34] [35] [36] [37] .
Limitations of the CNV assay
In addition to the absence of a defined macula in mice, the rodent laser trauma model obviously cannot be used to mimic the complexity of human pathology 4 . This model is generated with a wound-healing reaction that follows an insult at the level of Bruch's membrane and relies heavily on inflammation 38, 39 ; in contrast, in AMD, genetic susceptibility has a major role 40 . Factors important for the generation of the model may or may not occur in patients with exudative AMD. The involvement of VEGF 41 and placental growth factor 24 in the progression of experimental CNV has led to the clinical development of specific antagonists, such as ranibizumab 21 and aflibercept (VEGF trap, eye) 10 . Key features of AMD, such as subretinal pigmented epithelium (RPE) deposits (drusen) and the influence of age, are either absent or not crucial in this experimental model. Limitations of the assay also include the requirement of pigmented mice (BL6 mice are preferred) for laser reaction, the necessity of a trauma to induce CNV (no spontaneous development) and spontaneous regression (after 14-21 d) . This model is suitable to study exudative AMD but not the atrophic form of this ocular disorder. An important drawback of the model is that it cannot be used to test primate-specific reagents. To overcome this limitation, it is sometimes possible to use mice expressing the human homolog of the protein of interest. For example, to test human-specific VEGF antagonists, a transgenic mouse strain that expresses human VEGF in photoreceptors has been used as an alternative 42 .
Experimental design
The general protocol for CNV induction involves laser burning of Bruch's membrane after administering anesthesia to the mouse and dilating its pupils, eye resection at defined time point(s), imaging and quantification of angiogenesis and/or inflammation ( Fig. 1) . After anesthesia and pupil dilatation, a laser burn is first induced using a green Argon laser focused on the RPE. The presence of a bubble confirms the success of the laser impact. Mice are housed in the animal facility during the indicated time period (refer to the PROCEDURE). During this period, treatments can be applied to the mice. After killing the mice, the eyes are resected, and the choroid is either flat-mounted for immunohistological staining, embedded in a paraffin block or frozen, or used for protein or nucleic acid extraction. Blood sample analysis can also be performed, such as for metabolomics studies (Fig. 1) .
Experimental animals. This protocol is applicable to mice older than 2 weeks when the eyes are open and can be used to evaluate the effects of exogenous agents and/or genetic knockin or knockout. Adult C57BL/6J mice 6-8-week old weighing 18-20 g are the most appropriate for the assay, although the model can be applied to other mouse backgrounds provided they have pigmented eyes. It is worth noting that aged mice exhibit more severe CNV 43 . The sex of the mice does not appear to influence the assay substantially, except for older female mice, which develop more severe CNV than do male mice 44 . Laser burns are induced typically at the 3, 6, 9 and 12 o'clock positions around the optic disc in compliance with national and local ethical committees (Supplementary Video 1).
All mice must be treated in accordance with the Association for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research (http:// www.arvo.org/). Anesthesia and euthanasia must be performed in accordance with the local animal use committee. The use of ketamine and xylazine mixtures is not recommended because it can lead to serious side effects. At high doses of anesthetic, an acute and reversible cataract can occur, leading to lens clouding, which can reduce the visibility of the eye fundus and disturb laser focusing 45 .
Because of the inherent variability in animal experiments and because some laser impacts do not result in CNV (~70% of impacts are successful), it has proven necessary to use at least six mice, with four impacts per eye per experimental group, and to repeat experiments at least twice. We recommend two types of control groups. The first control group is not subjected to laser induction when comparing transgenic mice and/or evaluating proteins or RNAs or performing metabolomics studies. The second control group comprises mice subjected to laser burns and injected with the vehicle buffer alone for drug efficiency testing.
When evaluating pre-miRNA or siRNA, appropriate scramble sequences are recommended as controls. In cases of BM engraftment, an experimental group comprising irradiated and BMengrafted mice is mandatory because we have observed that BM engraftment can impact CNV formation 5, 19 . In general, the use of one eye for drug testing and the second eye as a control is useful because it controls for variation between mice. However, systemic dissemination of the drug is likely to occur. For example, intraocular injections of bevacizumab suppress subretinal neovascularization in the injected eye and also cause significant suppression in the other ('fellow') eye, indicating a systemic effect. In contrast, this is not the case for intraocular injections of ranibizumab 42 . Therefore, investigators should rule out systemic effects in the fellow eye with the drug being tested.
Statistical analysis.
To compare the effects of different treatments or compounds (I), including the control groups, on the chosen response, a linear mixed model has to be constructed that corresponds to the experimental setup. The following model can be used:
where y ijkl is the response measured (CNV surface), τ i denotes the fixed effect of the treatments i = 1, i (staining background, drugs), A j is the random effect owing to mouse variability (j = 1,…,6) (individual mouse variability), B k(j) is the random effect of the eyes (k = 1,2) nested into the animal factor (right or left eye) and ε ijkl represents the residual random error (l = 1,…,4 impacts). The significance of the treatment factor τ i of the model is assessed by comparing its P value to the significance level, e.g., α = 0.05. If found significant (P value <α), adequate post hoc comparisons of each treatment versus the control group or adequate linear contrasts can be performed to identify the promising treatments. We recommend using a hierarchical mixed ANOVA for three factors. It is worth noting that, depending on the nature of the response, a generalized linear mixed model could be used to analyze the data in place of a linear mixed model that assumes a normal distribution of the response y ijkl .
Treatment procedure. Intravitreal injection can be performed during anesthesia just after laser induction. Eyes are locally anesthetized, and a first hole is made under the limbus with a 30-gauge needle. The eye is gently massaged with a cotton swab to remove a portion of the vitreous to avoid a post-injection reflux of vitreous and/or drug solution. Thereafter, 2 µl of drug solution in PBS is intravitreously injected through the initial hole using a 34-gauge Hamilton syringe. Mice injected with PBS alone are used as controls. An alternative procedure consists of direct injection using pulled glass micropipettes attached to a Harvard pump 46 . The latter is easier and less traumatic but may induce reflux of some drug solution.
For testing compounds, recombinant proteins 27 or drugs 25 can be administered through single or multiple i.p. injections in a 200-µl solution volume. Standard vehicle-alone treatments should be included for comparison. When evaluating neutralizing antibodies 23, 24 , appropriate control antibodies should be used. Recombinant adenovirus (e.g., 7 × 10 8 plaque-forming units) can be i.v. injected. According to regulatory constraints, virally infected mice are permanently housed under BL2 containment, and sample analyses must be conducted in compliance with the governmental and institutional rules.
The involvement of BM-derived cells is demonstrated in BM transplantation experiments 5, 19, [47] [48] [49] [50] . BM transplantation experiments involve the isolation of BM cells from tibias and femurs of donor mice between 8 and 12 weeks of age. Here BM cells from transgenic mice expressing enhanced GFP under the control of the β-actin promoter, C57BL/6-Tg(ACTbEGFP)10sb, are collected and grafted into previously irradiated recipient C57BL/6J mice. Total body lethal irradiation is performed and varies from 8-12 Gy for immunocompetent mice. Because of variation in the acute lethal response to whole-body irradiation depending on mouse strain and age, the investigators must define the lethal dose of irradiation. At least 5 weeks are necessary for the mice to recover after BM transplantation. Percentage chimerism can be measured using antibodies against donor-specific cellsurface proteins via flow cytometry analysis of blood and BM cells. For GFP + BM-derived cell transplantation, the percentages of GFP + donor cells in blood and BM samples are determined by flow cytometry 5, 19 .
Sample excision and processing. To visualize the neoformed vascular network, FITC-dextran can be i.v. injected 3 min before mouse killing. Both eyes are resected, briefly cleaned and prepared for histological analysis, frozen for RNA or protein extraction, or fixed in 1% (wt/vol) paraformaldehyde (PFA) for flat-mount analysis. For the latter, eyes are cleaned more thoroughly after fixation. The excess muscle and optic nerve are removed (Supplementary Video 2). The cornea is dissected and removed. The retina is carefully separated from the choroid, and four cuts are made to easily flatten the choroid onto the slide (Supplementary Video 3). For immunohistochemical analyses of eye sections, we have noted that blue and brown chromogenic substrates frequently used on paraffin film sections are difficult to distinguish from the melanin of RPE and choroid. Therefore, we prefer to use eye cryosections for fluorescence immunostaining. At the end of the assay, blood samples can also be collected for further analyses, such as ELISA and metabolomics studies.
Imaging and quantification. Quantification can be performed on either tissue sections or flat-mounted choroids. Quantitative morphometric assessment of neovascular lesion thickness in eye sections is performed using a computer-assisted image analysis system. Microscopy images (working magnification of ×200) of hematoxylin-stained eye sections are acquired via a video camera, and digitized and measured using ImageJ software. Frozen serial sections are cut throughout the extent of each burn, and the thickest lesions (at least five sections per lesion) are used for quantitation. Neovascularization is estimated by the ratio (B/C) of lesion thickness from the bottom of the pigmented choroidal layer to the top of the neovascular membrane (B) to the thickness of the intact pigmented choroid adjacent to the lesion (C) (Fig. 2a) . Histological immunostaining with anti-platelet endothelial cell adhesion molecule (PECAM) and anti-collagen IV antibodies is used to assess the presence of newly formed blood vessels (Fig. 2b) . The advantage of this quantification method (over surface estimation) is that the B/C ratio is independent of the oblique section (Fig. 2c) , whereas section orientation influences the measurement of a lesion's surface. However, this method is time-consuming and requires an entire eye to obtain sufficient sections through all impacts for objective quantification.
We routinely use FITC-dextran-labeled flat-mounted choroid for rapid quantification of neoformed vessels ( Fig. 2d-g ). For 2D analysis, images obtained by fluorescence microscopy are digitized using a three-color video camera. ImageJ is used to measure the total area (in µm 2 ) of CNV associated with each burn. A calibration image is taken from a slide with a grating of known size. An established and constant threshold in pixels (corresponding to threshold fluorescence) is used to quantify neovascularization. The optimum time point to assess CNV formation is typically at day 7 or day 14 ( Fig. 3) . Later, an active healing process begins, and lesion size decreases.
For 3D analysis of FITC-dextran-labeled microvessels, images are binarized using the same threshold for all images, and the area of neovascularization is quantified. The spatial distribution of fluorescence is examined using an inverted confocal laser microscope. After 3D fluorescence image construction, the CNV volume is determined using the image analysis toolbox of Matlab 7.9.
Immunofluorescence staining is required to obtain more information on microvessels, including the identification of endothelial cells, mural cells (pericytes and smooth muscle cells), inflammatory cells (Figs. 2 and 4) and BM-derived cells (Fig. 5) . Staining can be performed on eye sections and on whole-mounted choroid (Figs. 2-4) .
Biological analyses.
To evaluate the kinetics of mRNA expression using semi-quantitative RT-PCR or protein production using western blot, CNV is induced in mice with multiple argon laser burns (30 impacts per eye). The posterior segments (RPE-choroid complex without neural retina) are excised and immediately frozen in liquid nitrogen before RNA or protein extraction. and the exposure time set to 0.050 s. ! cautIon The appropriate power to rupture Bruch's membrane while minimizing damage to the surrounding choriocapillaris varies with different lasers and can even change with the same laser depending upon the age of its fiber optic cable. Therefore, our recommendations for power settings are suggestions, and the laser output must be calibrated. For laser calibration, perform burns on the retina of a 'calibration mouse' starting with relatively low power and gradually increasing until the lowest power that reproducibly ruptures Bruch's membrane is identified with the creation of a bubble. A major pitfall is using too much power, which damages the surrounding choriocapillaris and reduces or completely prevents CNV. ! cautIon Check that the Dr Filter is switched on in order to protect the operator from laser reflection. ! cautIon Do not look at the laser flash. Any laser beam reflection on any glass surface may damage the experimenter's retina.
proceDure BM transplantation (optional) • tIMInG 1 d for transplantation and 5 weeks for BM restoration
 crItIcal This section must be performed 5 weeks before laser induction to allow BM reconstruction.
 crItIcal This section must be performed by licensed and qualified individuals according to the institutional guidelines.
 crItIcal This section must be performed under sterile conditions. 1| Irradiate recipient mice (8-to 10-week-old) with a single dose of 9 Gy.
2|
Kill the donor mice (8-10 weeks of age) by cervical dislocation (or in accordance with guidelines of the local animal use committee).
3|
Remove both posterior limbs with scissors. Remove as much hair, skin and muscle as possible without compromising the marrow cavity. Remove a portion of the pelvic bone if necessary.
4| Pour ~8 ml of culture medium in a 10-cm diameter culture dish.
5|
Thoroughly scrap the tibia and femur of all fascia, connective tissue and muscle. Separate bones at the knee joint. Store bones in medium until all bones are collected for the next step (maximum 1 h).
6|
Carefully clip the epiphysis and distal ends of each bone. By using ~2 ml of medium, slowly flush BM with a 27-gauge needle into a tube.
7|
Dissociate cell aggregates using a pipette, and pass the cell suspension through a 70-µm cell strainer.
8|
Count the total number of cells using a Thoma slide.
9|
Inject BM cells (10 7 per animal) i.v. into irradiated recipient mice (from Step 1).
10|
If you are using GFP donor mice, confirm BM restoration after 5 weeks by analyzing the proportion of GFP + cells in blood and BM samples via flow cytometry (~75% restoration should be achieved). Alternatively, confirm BM cross-transplantation by genotyping the BM.
Material preparation and laser induction • tIMInG 45 min for 12 mice 11|
Place the slit lamp where it is easily accessible to both users, and place the mouse support on the chin rest.  crItIcal step Before any manipulation, confirm the health of the mice's eyes macroscopically, and discard any mouse with a cataract or visible defect of the cornea, which diminishes eye clarity.  crItIcal step Prewarm the warming plate to 34 °C before the procedure so that it is at this temperature during pupil dilation and after the laser induction step to lay the mice on it until they wake to prevent hypothermia owing to anesthesia. 14| Place a drop of tropicamide in each eye of each mouse to dilate the pupils.
15|
Wait for 3-5 min until pupils are completely dilated before placing the mouse on a prewarmed (34 °C) mouse support for laser induction.
16|
Confirm that pupils are dilatated.  crItIcal step The pupils must be completely dilated to see the entire eye fundus.
? trouBlesHootInG 17| Place the mouse on the support for laser induction (this should be done by the mouse operator, MO).  crItIcal step This and the following six steps require two researchers: the MO manipulates the mouse and the laser operator (LO) performs the laser induction.
18| LO: set the height of the mouse support with the chin rest adjuster to place the mouse's eye in front of the laser beam.
19| MO: place the mouse perpendicular to the laser beam and protrude the eye completely to position the eye for laser induction.  crItIcal step The eye must be well deorbited to facilitate impact positioning.
20| MO: place a drop of GenTeal (or Goniosol) on the corner of a coverslip, and place it carefully on the eye as a contact lens to convert the curved surface of the cornea to a planar surface. ! cautIon For operator safety and to prevent laser beam reflection toward the LO, do not place the cover glass perpendicularly.  crItIcal step To prevent eye immobilization, do not put too much pressure on the cover glass.
21| LO: confirm that the cover glass is in place and acts as a contact lens. The mouse is now ready for laser induction.
? trouBlesHootInG 22| LO: switch on the laser photocoagulator and focus the laser beam on the RPE of the eye fundus. ! cautIon Visualize the retina and precisely focus the aiming beam on the retina before activating the laser. Defocusing the aiming beam could lead to burns that do not rupture Bruch's membrane and fail to yield CNV.
23| LO: induce four impacts (at the 3, 6 and 9 and 12 o'clock positions) or more impacts (i.e., 30-40 impacts) around the optic nerve using the laser's trigger pedal. ! cautIon Do not look at the laser flash. The laser beam's reflection on the cover glass may cause damage to the retina.  crItIcal step A bubble should appear, confirming the efficiency of laser induction (supplementary Video 1). Only burns that produce a bubble should be included in the study.  crItIcal step Avoid laser impacts to the retinal vessels of the mouse to prevent intraocular hemorrhage.
24|
After laser induction, lay the mouse on the warming plate until it wakes to prevent hypothermia owing to anesthesia. If necessary, proceed with the following steps while the mouse is still under anesthesia.  crItIcal step This injection must be performed under an operation microscope directly after laser induction when the mice are still under anesthesia.  crItIcal step This step must be performed by licensed and qualified individuals according to the institutional guidelines.  crItIcal step A complement to anesthesia is given to waking mice (i.p. injection of anesthetic at an appropriate dose in accordance with the local animal use committee, for instance, use 100 µl of avertin for a 20 g mouse that already received 350 µl). (vi) Gently press on the eye with a cotton swab to extrude more vitreous and gain volume in the posterior chamber for drug injection. (vii) Insert the 34-gauge needle of a Hamilton syringe through the puncture hole at a 45° angle relative to the scleral surface.  crItIcal step Avoid injuring the lens with the needle, which can lead to secondary cataracts.  crItIcal step Prevent any bleeding in the eye, which can lead to infection.  crItIcal step Do not inject air bubbles into the vitreous. (viii) Slowly inject 2 µl of the drug into the posterior chamber of the mouse eye, and wait a few seconds before removing the needle from the eye.  crItIcal step Take care to maneuver around the lens, and avoid delivering the solution close to the retina. ? trouBlesHootInG ? trouBlesHootInG Troubleshooting advice can be found in table 1. Step 31B immunostaining for cryostat sections: 4 h
Step 31C, immunostaining for whole mounts: 3 h over 2 d Steps 31D and E, mRNA and protein analysis: half day for each
Step 32, image analysis of neoformed vessels: half day (option A), half day (option B) and 5 min per impact (option C) Box 1, metabolomics study: 20 min per sample and 2 h for statistical analysis
antIcIpateD results
The development of neovascular lesions over time can be evaluated in a typical experiment in which laser burninduced lesions are determined at different time points (Fig. 3) . CNV is expected to take place within 5 d. At day 7, a typical mushroom-like lesion is observed with a regression of neoformed blood vessels from day 21. Inflammatory cells rapidly infiltrate the CNV lesion with a neutrophil peak at day 1 to day 3, followed by a macrophage peak at day 5. Inflammatory cells are no longer detected at day 7 (Fig. 4 ).
An illustrative assay using a tyrosine kinase inhibitor (sunitinib) 52 is shown in Figure 5a . The CNV surface measurement reveals a marked reduction in vessel formation upon oral administration of the anti-angiogenic inhibitor (Fig. 5a) . Examples of CNV quantifications by the determination of B/C ratio on eye section (Fig 5b) , CNV area ( Fig. 5c ) and CNV volume ( Fig. 5d and supplementary Video 4) on flat-mounted choroid (Fig. 5c) are shown by applying the model to MMP13-deficient mice. This experiment also emphasizes the interest in using genetically modified mice in order to unravel molecular mechanism underlying AMD 8, 19, [24] [25] [26] [27] [28] 53, 54 . BM-derived cell recruitment in the choroidal lesion is demonstrated by the transplantation of BM isolated from GFP-transgenic mice into C57Bl/6J mice 5, 49, 50 (Fig. 5e,f) .
The 1 H-NMR metabolomics approach emerged recently as a powerful method for identifying changes in small-molecular weight organic molecules (metabolites) associated with pathologies [55] [56] [57] [58] . This method is suitable to discriminate mice displaying different angiogenic response. A proof of principle is shown in a miRNA study demonstrating CNV reduction through pre-miR administration (e.g., miR21, a miR with anti-angiogenic activity) 13 (Fig. 6) . In this assay, four different animal groups are discriminated: (i) control mice not subjected to laser and noninjected (group 1), (ii) mice subjected to laser and either noninjected (group 2) or injected with a scramble pre-miR (group 3) and (iii) laser-induced mice injected with pre-miR21 (group 4). 
